COVID-19：东京理科大学：甲氟喹消除病毒细胞
~ 有可能成为新的 COVID-19 治疗药物 ~
研究总结：
甲氟喹：
对已被批准的抗寄生虫药和抗原生动物药的感染细胞系进行了筛选。
因此，抗疟药甲氟喹对新型冠状病毒（SARS-CoV-2）显示出比羟氯喹更高的抗病毒作用。
高抗病毒作用：
SARS-CoV-2吸附在细胞上后，它抑制了侵袭过程。
也有人提出，当与抑制病毒复制的奈非那韦联合使用时，可以获得协同抗病毒作用。
病毒消除时间减少了 6.1 天：
根据数学模型，估计以标准治疗中使用的浓度施用甲氟喹可使病毒从体内清除减少 6.1 天。
甲氟喹给药研究
表明甲氟喹是治疗 COVID-19 的有希望的候选药物，未来有待进一步研究。
NEWS & EVENTS ｜ 东京理科大学
https://www.tus.ac.jp/today/archive/20210630_8167.html
Tokyo University of Science & Collaborators Find Mefloquine Could Target COVID-19
Recently, researchers from the Tokyo University of Science
along with scientists from the National Institute of Infectious Diseases,
Kyushu University,
The University of Tokyo,
Kyoto University,
Japanese Foundation for Cancer Research, and Science Groove Inc.have identified an anti-malarial drug, mefloquine (which is incidentally a derivative of hydrochloroquine),
that is effective against SARS-CoV-2. Their findings are published in Frontiers in Microbiology.
In a breakthrough study,a team of scientists
identified mefloquine as the drug with the highest anti-SARS-CoV-2 activity among the tested compounds.
In fact, when comparing in a lab environment—that is, study in cell line involving humanized lung cells,
the drug was superior to other quinoline derivatives such as hydroxychloroquine.
The team further explored mefloquine’s mechanism of action.
Dr. Watashi explains the process,
In our cell assays, mefloquine readily reduced the viral RNA levels when applied at the viral entry phase but showed no activity during virus-cell attachment.
This shows that mefloquine is effective on SARS-COV-2 entry into cells after attachment on cell surface.